Acrux Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
27,970.00
11,130.00
12,981.00
243.00
14,182.00
Depreciation, Depletion & Amortization
1,413.00
1,425.00
1,492.00
1,560.00
618.00
Other Funds
745.00
597.00
261.00
11,092.00
5,801.00
Funds from Operations
30,128.00
12,704.00
13,812.00
8,590.00
9,552.00
Changes in Working Capital
6,243.00
2,185.00
2,694.00
3,214.00
4,270.00
Net Operating Cash Flow
36,371.00
10,519.00
16,506.00
5,376.00
5,282.00
Capital Expenditures
39.00
66.00
236.00
629.00
296.00
Net Investing Cash Flow
39.00
66.00
236.00
629.00
296.00
Cash Dividends Paid - Total
33,346.00
13,322.00
9,992.00
-
-
Net Financing Cash Flow
33,346.00
13,322.00
9,992.00
-
-
Net Change in Cash
2,935.00
2,707.00
6,292.00
4,614.00
5,504.00
Free Cash Flow
36,332.00
10,453.00
16,270.00
4,747.00
5,578.00
Deferred Taxes & Investment Tax Credit
-
448.00
922.00
3,819.00
1,789.00
Exchange Rate Effect
51.00
162.00
14.00
133.00
74.00

About Acrux

View Profile
Address
103-113 Stanley Street
West Melbourne Victoria (VIC) 3003
Australia
Employees -
Website http://www.acrux.com.au
Updated 07/08/2019
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The firm develops and commercializes pharmaceutical products using unique technology to administer drugs through the skin. It operates through the following geographical segments: Australia, Switzerland, United States, and Other.